News

Previously Dr Mason was senior vice president of business development at Cambridge Antibody Technology. Dr Mason holds a BSc degree in immunology from University College London and an

The new findings show that Apoptone treatment significantly reduced tumor volume (p < 0.05), and delayed tumor-doubling time relative to that in vehicle-treated animals. An analysis of tumor

Mr Partridge was appointed COO of Visa and interim president of Visa USA in July 2007. He joined Visa USA in October 1999 and has served as president

Mr Brewer replaces Emilio Cordova who has resigned from BASi to pursue other opportunities. Most recently Mr Brewer consulted with companies to develop and implement new business strategies.

Under the contract, PharmAthene will receive initial funding of approximately $13.2 million during a ‘base period’ of performance. During this time the company will be responsible for preclinical

The trial showed that microplasmin was generally well tolerated and also provided some preliminary efficacy data. The MITI IV trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled,

In this double-masked Phase II trial, patients were initially treated with either fixed monthly or quarterly dosing for 12 weeks and then continued to receive treatment for another

The three-year contract provides up to $24.9 million of funding for manufacturing of clinical lots, for non-clinical safety and efficacy studies, and for stability studies to further demonstrate

The proposed indication for prasugrel is for the treatment of patients with acute coronary syndromes being managed with an artery-opening procedure known as percutaneous coronary intervention. Daiichi Sankyo